Investing
Medivation Jumps on Prostate Cancer Drug Test (MDVN, DNDN, JNJ)
Published:
Last Updated:
Shares of development-stage drug maker Medivation Inc. have risen sharply today as the company said that its MDV3100 late-stage prostate cancer drug for patients who have failed chemotherapy extends life expectancy by 4.8 months. The drug does not challenge Dendreon Inc.’s (NASDAQ: DNDN) Provenge prostate cancer treatment, which attacks early-stage prostate cancer, but will compete with Johnson & Johnson’s (NYSE: JNJ) Zytiga late-stage drug.
Medivation’s shares are up nearly 24% at $68.59 after posting a new 52-week high of $68.81 earlier. See today’s story on Dendreon and Provenge here.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
